Orphazyme stock in free fall after in-court restructuring request

Danish biotech Orphazyme is once again being punished by investors.
Photo: Niels Hougaard/Jyllands-Posten/Ritzau Scanpix
Photo: Niels Hougaard/Jyllands-Posten/Ritzau Scanpix
by ANDREAS LØNSTRUP, translated by daniel pedersen

On Friday around noon local time, Orphazyme’s stock had dropped 29.6 percent at DKK 5.92 (USD 0.87) on the Copenhagen exchange.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading